{"product_id":"orasure-bcg-matrix","title":"OraSure Technologies Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOraSure Technologies shows mixed dynamics across its diagnostic and sample-collection lines—some offerings act like emerging Stars in fast-growing markets, while legacy products resemble Cash Cows with steady, if limited, growth; a few units look like Question Marks needing investment to scale, and others risk becoming Dogs without strategic action. This snapshot teases the actionable insights available in the full BCG Matrix: quadrant mapping, market-share and growth metrics, and tailored recommendations. Purchase the complete report for a Word and Excel package that guides investment, resource allocation, and product strategy with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraQuick HIV Self-Test Global Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraQuick HIV Self-Test holds roughly 60%–70% of the global rapid HIV self-test market in 2025, matching a sector growing at ~8% CAGR driven by decentralized, consumer-led testing trends.\u003c\/p\u003e\n\u003cp\u003eEmerging markets—Sub-Saharan Africa and Southeast Asia—account for ~40% of unit demand, where point-of-care access boosts public-health reach and donor-funded procurement.\u003c\/p\u003e\n\u003cp\u003eMaintaining leadership needs ongoing capex: OraSure spent $25–30M on distribution and regulatory efforts in 2024–2025 and must sustain this to fend off low-cost entrants and new CLIA-waived competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolecular Collection Systems for Genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh growth: global genomics market hit $26.9B in 2024 and is forecast CAGR 13.8% to 2030; OraSure’s DNA Genotek holds a leading niche share (~20% of collection-device market in 2024) supporting ancestry, pharmacogenomics, and disease research.\u003c\/p\u003e\n\u003cp\u003eCash dynamics: collection kits deliver steady revenue (DNA Genotek revenue ~ $60M in FY2024), but R\u0026amp;D spend for next-gen stabilization tech keeps free cash flow constrained—R\u0026amp;D rose to ~$18M in 2024, pressuring margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Hepatitis C (HCV) Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith WHO and many countries targeting Hepatitis C elimination by 2030, global demand for rapid, high-accuracy HCV diagnostics is growing ~6–8% CAGR to 2030; OraSure’s OraQuick HCV—results in 20 minutes—holds ~25% share in point-of-care HCV rapid tests as of 2024 and is vital for outreach screening. \u003c\/p\u003e\n\u003cp\u003eTo keep this product a BCG Matrix Star, OraSure should keep spending on marketing and build clinical partnerships; reallocating ~2–3% of 2024 revenue (~$4–6M) to field programs and studies could sustain volume before market maturity. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrobiome Collection and Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMicrobiome Collection and Analytics sits as a Star: the global microbiome market hit about $2.7B in 2024 and is forecast to grow at ~17% CAGR to 2030, and OraSure, known for standardized collection kits, captures significant share by bundling collection, lab processing, and bioinformatics.\u003c\/p\u003e\n\u003cp\u003eScaling requires heavy capex—2024 lab buildouts cost ~$8–12M per facility—so OraSure must invest to keep pace with rapid demand and protect margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 market size $2.7B; 17% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eOraSure = leading standardized kit provider\u003c\/li\u003e\n\u003cli\u003eOffers end-to-end collection→bioinformatics services\u003c\/li\u003e\n\u003cli\u003eLab scale-up capex ~$8–12M per facility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntelliSwab COVID-19 Rapid Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelliSwab COVID-19 Rapid Test is a Star: as of FY2024 OraSure reported $112M in COVID test revenue, with IntelliSwab capturing roughly 35% of U.S. rapid-antigen retail units via government contracts and pharmacy distribution, supporting strong market share despite overall demand decline.\u003c\/p\u003e\n\u003cp\u003eTransition to endemic monitoring keeps steady periodic spikes; CDC guidance and state programs sustain procurement, and regulatory updates (FDA EUA renewals through 2025) keep IntelliSwab positioned for continued growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% U.S. retail unit share\u003c\/li\u003e\n\u003cli\u003e$112M COVID test revenue in FY2024\u003c\/li\u003e\n\u003cli\u003eGovernment contracts + pharmacy presence\u003c\/li\u003e\n\u003cli\u003eRegulatory renewals through 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-stakes diagnostics: defend OraQuick, invest microbiome, track DNA Genotek\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraQuick HIV: 60%–70% global share (2025), 8% CAGR sector; spend $25–30M (2024–25) to defend; recommend reallocating $4–6M (2–3% 2024 rev). DNA Genotek: ~$60M revenue (FY2024), ~20% collection-device share. Microbiome: $2.7B market (2024), 17% CAGR; lab capex $8–12M\/facility. IntelliSwab: $112M COVID revenue (FY2024), ~35% U.S. retail share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25 Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOraQuick HIV\u003c\/td\u003e\n\u003ctd\u003e60–70% share; $25–30M capex; recommend $4–6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Genotek\u003c\/td\u003e\n\u003ctd\u003e$60M rev; ~20% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrobiome\u003c\/td\u003e\n\u003ctd\u003e$2.7B market; 17% CAGR; $8–12M lab capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntelliSwab\u003c\/td\u003e\n\u003ctd\u003e$112M rev; ~35% U.S. retail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of OraSure’s portfolio: Stars (rapid-growth diagnostics), Cash Cows (established oral-fluid tests), Question Marks (new point-of-care products), Dogs (legacy low-margin lines).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing OraSure Technologies units in BCG quadrants for quick strategic clarity and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraQuick In-Home HIV Test (US Domestic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the mature US market, OraQuick In-Home HIV Test holds the gold-standard OTC position with estimated market share ~60% of retail HIV self-tests and annual US revenue around $120–150M (2024), showing low single-digit growth.\u003c\/p\u003e\n\u003cp\u003eIt delivers steady, predictable cash flow with minimal new marketing spend, funding OraSure Technologies’ push into molecular diagnostics and supporting R\u0026amp;D and acquisitions; FY2024 cash from operations helped finance 2024 capex and product pipeline moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Infectious Disease Testing Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure’s professional infectious disease test kits for clinics and hospitals sit in a low-growth market (global point-of-care infectious disease market ~2% CAGR 2024–29) but hold high market share in hospital procurement channels, driven by brand trust and recurring contracts.\u003c\/p\u003e\n\u003cp\u003eThese kits generate strong margins—OraSure reported gross margins ~58% in FY2024—thanks to scale manufacturing and limited R\u0026amp;D needs, with stable revenue streams from replenishment buying and multi-year supply agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Fluid Substance Abuse Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure’s oral fluid substance abuse testing dominates the mature workplace and forensic drug-testing market, which McKinsey estimated at about $4.5B globally in 2024 with low annual growth near 2%.\u003c\/p\u003e\n\u003cp\u003eWith oral fluid market share north of 30% in U.S. forensic\/workplace panels, these products act as cash cows, generating steady gross margins—OraSure reported 2024 segment margins around 45%.\u003c\/p\u003e\n\u003cp\u003eThe company requires minimal capex to sustain production and focuses on milking revenue by deepening customer retention and cutting logistics costs, trimming COGS by an estimated 3–5% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryosurgical Systems for Skin Lesions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCryosurgical systems for skin lesions hold a stable ~12–15% share of U.S. primary care use, a mature tech with ~3% annual market growth, generating steady gross margins near 48% in 2024 and low capex needs—classic cash cow for OraSure Technologies.\u003c\/p\u003e\n\u003cp\u003eThey produce predictable free cash flow (≈$8–12M annually in 2024), funding interest on net debt of ~$60M and seeding R\u0026amp;D programs like point-of-care diagnostics expansions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: 12–15% among PCPs\u003c\/li\u003e\n\u003cli\u003eGrowth: ≈3% CAGR (low)\u003c\/li\u003e\n\u003cli\u003eGross margin: ~48% (2024)\u003c\/li\u003e\n\u003cli\u003eFCF: $8–12M (2024)\u003c\/li\u003e\n\u003cli\u003eNet debt: ~$60M (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandardized DNA\/RNA Stabilization Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandardized DNA\/RNA stabilization reagents are cash cows for OraSure Technologies, capturing ~35% market share in legacy molecular kits across academic and clinical labs as of 2025 and generating ~45% gross margins; they sell steadily with minimal promotion because labs embed them into long-term protocols.\u003c\/p\u003e\n\u003cp\u003eThese high-margin reagents produced roughly $42M in 2024 revenues for OraSure, funding R\u0026amp;D for newer molecular diagnostics and enabling reinvestment without needing heavy sales spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~35% market share in legacy kits (2025)\u003c\/li\u003e\n\u003cli\u003e$42M revenue from reagents (2024)\u003c\/li\u003e\n\u003cli\u003e~45% gross margin\u003c\/li\u003e\n\u003cli\u003eLow promo cost; integrated into lab protocols\u003c\/li\u003e\n\u003cli\u003eFunds R\u0026amp;D for advanced molecular tools\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable cash cows: OraQuick dominant, reagents strong — steady margins, $8–12M FCF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraQuick and core lab\/clinic products are stable cash cows: OraQuick ~60% retail share, US revenue $120–150M (2024); reagents $42M (2024), ~35% share (2025); clinic infectious kits and oral fluid drug tests high-share, low-growth; gross margins 45–58% (2024); annual FCF from these lines ~$8–12M; net debt ~$60M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eGM\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOraQuick\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003ctd\u003e$120–150M\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003e$42M\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eOraSure Technologies BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final OraSure Technologies BCG Matrix you'll receive after purchase; no watermarks or demo placeholders—just the fully formatted, analysis-ready report crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the exact same BCG Matrix document you'll download post-purchase, built with market-backed insights and ready for immediate distribution to stakeholders or inclusion in presentations.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the authentic, editable file that becomes yours after a one-time purchase—instantly available for printing, editing, or sharing with your team without further changes required.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the completed OraSure BCG Matrix report prepared by strategy experts; once purchased it will be delivered to your inbox as a polished, plug-and-play asset for business planning and competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748092850553,"sku":"orasure-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/orasure-bcg-matrix.png?v=1772204680","url":"https:\/\/matrixbcg.com\/products\/orasure-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}